MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Published on :

MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc.,  a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.